Key result
5-iminodaunorubicin retains antileukemic activity in mice while demonstrating reduced cardiotoxicity by electrocardiographic measurements in rats and nonmutagenic properties.
Why the study?
Does 5-iminodaunorubicin reduce cardiotoxicity while retaining antileukemic activity compared to daunorubicin or adriamycin in preclinical models?
Population
Preclinical models: mice, rats, and Salmonella typhimurium
Comparison
5-iminodaunorubicin vs daunorubicin or adriamycin
Design
Preclinical
Authors
Loading...
Should not yet alter anthracycline use in leukemia; leaves open safer analogues for clinical translation.
Does 5-iminodaunorubicin reduce cardiotoxicity while retaining antileukemic activity compared to daunorubicin or adriamycin in preclinical models?
5-iminodaunorubicin is a novel anthracycline analogue that retains antileukemic activity while demonstrating reduced cardiotoxicity in preclinical models.
Tong et al. (1979) studied this question. 5-iminodaunorubicin retains antileukemic activity in mice while demonstrating reduced cardiotoxicity by electrocardiographic measurements in rats and nonmutagenic properties.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: